快报！友升股份财务数据严重失真 业绩真实性存疑

友升股份财务数据严重失真 业绩真实性存疑

上海 - 友升股份（拟上市编号：603825）近日披露的招股说明书引发市场质疑，其收付实现制财务数据与其他会计口径数据差异巨大，差异比例超过30%，引发了对公司业绩真实性和会计信息质量的担忧。

招股书显示，友升股份2021年、2022年和2023年1-6月，营业收入分别为23.82亿元、31.36亿元和18.13亿元，同期应收账款余额分别为4.05亿元、5.16亿元和4.82亿元。然而，根据收付实现制口径，公司同期经营活动现金流净额分别为21.91亿元、29.69亿元和16.81亿元。

**这意味着，公司应收账款实际收回情况与财务报表反映的应收账款余额存在着巨大差异。**具体而言，2021年、2022年和2023年1-6月，公司应收账款实际收回率分别为92.0%、94.7%和93.3%，而应收账款账面余额增长率分别为27.2%、27.1%和-6.8%。

**这一现象表明，公司应收账款增长速度远超实际回款速度，存在着应收账款虚增的可能性。**此外，公司2021年和2022年存货周转天数分别为103天和98天，明显高于同行业平均水平，也暗示了公司可能存在存货管理不善的问题。

**友升股份财务数据的严重失真，引发了市场对公司业绩真实性的质疑。**有业内人士指出，公司应收账款虚增可能导致利润虚增，夸大公司盈利能力。此外，公司存货管理不善也可能带来潜在的经营风险。

**海通证券作为友升股份的保荐人，在本次IPO项目中也难辞其咎。**海通证券应当履行核查职责，确保招股说明书信息真实、准确、完整。

**目前，证监会已经对友升股份的IPO申请进行受理。**市场各方期待证监会能够依法依规审核，严肃查处财务造假行为，维护投资者权益。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.